Clinical pharmacokinetics of alpha 1-antitrypsin in homozygous PiZ deficient patients.
A pharmacokinetic study of alpha 1-antitrypsin (ATT) was performed in 2 groups of homozygous PiZ-deficient patients (treated and untreated) and 1 group of healthy volunteers. The distribution of the 131I-labelled protein corresponds to a 3-compartment model. The intravenously administered protein diffused quickly to the extravascular compartment where some retention occurred. No significant difference in AAT metabolism was observed between the 3 groups. The half-life of the injected protein is slightly longer than 2.5 days. The AAT protein was not stored. These results confirm the observations collected during the clinical trials. That is, a weekly infusion is necessary to obtain stable serum AAT concentrations. Monthly infusions are unable to maintain a 'plateau' phase. The periodicity may be limited to every 2 weeks.
Constans
J
J
Faculty of Medicine, Internal Medicine Department, Purpan Hospital, Toulouse, France.
Carles
P
P
Boneu
A
A
Arnaud
J
J
Tufenkji
A E
AE
Pujazon
M C
MC
Tavera
C
C
D000328:Adult; D000368:Aged; D000704:Analysis of Variance; D005260:Female; D006207:Half-Life; D006720:Homozygote; D006801:Humans; D007275:Injections, Intravenous; D008297:Male; D008657:Metabolic Clearance Rate; D008875:Middle Aged; D010641:Phenotype; D000515:alpha 1-Antitrypsin / Q000008:administration & dosage / Q000493:pharmacokinetics*; D019896:alpha 1-Antitrypsin Deficiency
D000515:alpha 1-Antitrypsin